Clinical trial
Decitabine in Treating Patients With Myelofibrosis
NCT00095784 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00095784 |
|---|---|
| Title | Decitabine in Treating Patients With Myelofibrosis |
| Official title | A Phase II Study of Decitabine in Myelofibrosis |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Myelofibrosis, Secondary Myelofibrosis |
| Intervention type | Drug, Other |
| Interventions | Decitabine, Laboratory Biomarker Analysis |
| Enrollment | 21 |
| Start date | Sep 29, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Feb 22, 2026 |
| First posted | Nov 9, 2004 |
| Last update posted | Aug 24, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: